查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1468363

杜氏肌肉营养不良症药物市场按产品类型（皮质类固醇、疼痛管理药物）、治疗方法（突变抑制、外显子跳跃、类固醇治疗）、最终用户（医院、诊所、家庭护理机构）和地区 2024-2032

Duchenne Muscular Dystrophy Drugs Market by Product Type (Corticosteroids, Pain Management Drugs), Therapeutic Approach (Mutation Suppression, Exon Skipping, Steroid Therapy), End User (Hospitals, Clinics, Home Care Settings), and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 136 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年，全球杜氏肌肉营养不良症药物市场规模达23亿美元。杜氏肌肉营养不良症在大众中患病率不断上升、新产品批准和上市数量不断增加、政府提供良好报销政策的有利倡议以及推广针对特定目标的治疗方法，是推动市场发展的一些关键因素。

杜氏肌肉营养不良 (DMD) 药物用于治疗严重的 X 连锁遗传性疾病，即进行性肌肉营养不良，主要影响男性群体，很少影响女性。这种疾病的症状包括行走、站立和坐立困难以及言语困难，这可能导致骨骼肌和心肌进行性无力和丧失，也称为萎缩。 DMD 药物透过针对心臟和骨骼肌来增强患者的心肺功能。肌营养不良蛋白是维持肌肉完整性的关键蛋白质，其缺失或异常会导致 DMD。因此，大多数治疗 DMD 的药物都是基于肌肉营养不良蛋白的。 DMD 的其他一些主要治疗策略还包括与特定突变相关的基因疗法，这些突变可恢復肌营养不良蛋白的产生、膜稳定或补偿蛋白的上调，以及减少发炎级联和/或增强肌肉再生。

杜氏肌肉营养不良症药物市场趋势：

主要製造商批准和推出的新产品数量不断增加是推动市场成长的重要因素。这可以归因于杜氏肌肉营养不良症在群众中的发生率不断上升。与此一致的是，临床试验的大幅增加以及强大的产品线的存在正在为市场提供动力。此外，由于诊断技术的不断创新，突变特异性疗法的出现也对市场产生了积极影响。除此之外，针对婴儿、女性和非行走患者等服务不足类别的 DMD 准确诊断和治疗的广泛研发 (R&D) 活动正在推动市场发展。然而，药物临床疗效检查标准化程序的缺乏、诊断和预测的延迟以及基因治疗成本的上升正在成为市场成长的限制因素。相反，有利的政府措施提供了良好的报销政策，并推广针对特定目标的治疗，正在促进市场成长。在市场上创造利润丰厚的成长机会的其他一些因素包括快速城市化、医疗基础设施的改善、产品高端化的趋势以及大众可支配收入的增加。

本报告回答的关键问题

  • 全球杜氏肌肉营养不良症药物市场有多大？
  • 2024-2032年全球杜氏肌肉营养不良症药物市场的预期成长率是多少？
  • 推动全球杜氏肌肉营养不良症药物市场的关键因素是什么？
  • COVID-19 对全球杜氏肌肉营养不良症药物市场有何影响？
  • 根据产品类型，全球杜氏肌肉营养不良症药物市场的细分如何？
  • 根据治疗方法，全球杜氏肌肉营养不良症药物市场的细分情况如何？
  • 基于最终用户，全球杜氏肌肉营养不良症药物市场的细分如何？
  • 全球杜氏肌肉营养不良症药物市场的关键区域有哪些？
  • 全球杜氏肌肉营养不良症药物市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球杜氏肌肉营养不良症药物市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依产品类型

  • 皮质类固醇
    • 市场走向
    • 关键环节
      • 泼尼松龙
      • 强的松
      • 地夫可特
    • 市场预测
  • 疼痛管理药物
    • 市场走向
    • 市场预测

第 7 章：市场区隔：透过治疗方法

  • 突变抑制
    • 市场走向
    • 市场预测
  • 外显子跳跃
    • 市场走向
    • 市场预测
  • 类固醇治疗
    • 市场走向
    • 市场预测

第 8 章：市场区隔：依最终用户

  • 医院
    • 市场走向
    • 市场预测
  • 诊所
    • 市场走向
    • 市场预测
  • 家庭护理设置
    • 市场走向
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：驱动因素、限制与机会

  • 概述
  • 司机
  • 限制
  • 机会

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • FibroGen Inc.
    • Italfarmaco SpA
    • NS Pharma Inc. (Nippon Shinyaku Co. Ltd.)
    • PTC Therapeutics Inc.
    • Santhera Pharmaceuticals
    • Sarepta Therapeutics Inc.
Product Code: SR112024A6715

The global Duchenne muscular dystrophy drugs market size reached US$ 2.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.5 Billion by 2032, exhibiting a growth rate (CAGR) of 9.96% during 2024-2032. The rising prevalence of Duchenne muscular dystrophy among the masses, the increasing number of new product approvals and launches, and favorable government initiatives providing good reimbursement policies, along with promoting target-specific treatments, represent some of the key factors driving the market.

Duchenne muscular dystrophy (DMD) drugs are utilized to treat a severe X-linked genetic disorder of a progressive form of muscular dystrophy that primarily affects the male population, and rarely females as well. The symptoms of this disorder include difficulty walking, standing, and sitting, as well as speech difficulties, which can result in progressive weakness and loss, also known as atrophy, in the skeletal and heart muscles. The DMD drugs enhance cardiac and pulmonary functions in patients by targeting cardiac and skeletal muscles. Dystrophin is a key protein that maintains muscular integrity, and its absence or abnormality causes DMD. As a result, most of the drugs for the treatment of DMD are dystrophin-based. Some of the other primary treatment strategies for DMD also include genetic therapies linked to specific mutations which restore dystrophin production, membrane stabilization or upregulation of compensatory proteins, and a reduction of the inflammatory cascade and/or enhancement of muscle regeneration.

Duchenne Muscular Dystrophy Drugs Market Trends:

The rising number of new product approvals and launches by the major manufacturers is a significant factor driving the growth of the market. This can be attributed to the growing incidences of Duchenne muscular dystrophy among the masses. In line with this, a considerable rise in clinical trials, along with the presence of strong pipeline of products, is providing an impetus to the market. Moreover, the advent of mutation-specific therapies due to continual innovations in diagnostics is also impacting the market positively. Besides this, extensive research and development (R&D) activities focusing on accurate diagnosis and treatment of DMD for underserved categories, such as infants, females, and nonambulant patients, are propelling the market. However, the shortage of standardized procedures for the examination of the clinical efficacy of drugs, delayed diagnosis and prediction, and the rising costs of genetic therapeutics are acting as growth-restraining factors for the market. On the contrary, favorable government initiatives providing good reimbursement policies, along with promoting target-specific treatments, are contributing to the market growth. Some of the other factors creating lucrative growth opportunities in the market include rapid urbanization, improving medical infrastructure, emerging trend of product premiumization, and inflating disposable incomes of the masses.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global Duchenne muscular dystrophy drugs market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on product type, therapeutic approach, and end user.

Product Type Insights:

Corticosteroids

Prednisolone

Prednisone

Deflazacort

Pain Management Drugs

The report has provided a detailed breakup and analysis of the Duchenne muscular dystrophy drugs market based on the product type. This includes corticosteroids (prednisolone, prednisone, and deflazacort) and pain management drugs. According to the report, corticosteroids represented the largest segment.

Therapeutic Approach Insights:

Mutation Suppression

Exon Skipping

Steroid Therapy

The report has provided a detailed breakup and analysis of the Duchenne muscular dystrophy drugs market based on the therapeutic approach. This includes mutation suppression, exon skipping, and steroid therapy. According to the report, exon skipping represented the largest segment.

End User Insights:

Hospitals

Clinics

Home Care Settings

A detailed breakup and analysis of the Duchenne muscular dystrophy drugs market based on the end user has also been provided in the report. This includes hospitals, clinics, and home care settings. According to the report, hospitals accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for Duchenne muscular dystrophy drugs. Some of the factors driving the North America Duchenne muscular dystrophy drugs market include the rising number of new product approvals and launches, continual improvements in medical infrastructure, and the presence of several key players in the country.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global Duchenne muscular dystrophy drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include FibroGen Inc., Italfarmaco S.p.A., NS Pharma Inc. (Nippon Shinyaku Co. Ltd.), PTC Therapeutics Inc., Santhera Pharmaceuticals, Sarepta Therapeutics Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

  • 1. How big is the global Duchenne muscular dystrophy drugs market?
  • 2. What is the expected growth rate of the global Duchenne muscular dystrophy drugs market during 2024-2032?
  • 3. What are the key factors driving the global Duchenne muscular dystrophy drugs market?
  • 4. What has been the impact of COVID-19 on the global Duchenne muscular dystrophy drugs market?
  • 5. What is the breakup of the global Duchenne muscular dystrophy drugs market based on the product type?
  • 6. What is the breakup of the global Duchenne muscular dystrophy drugs market based on the therapeutic approach?
  • 7. What is the breakup of the global Duchenne muscular dystrophy drugs market based on the end user?
  • 8. What are the key regions in the global Duchenne muscular dystrophy drugs market?
  • 9. Who are the key players/companies in the global Duchenne muscular dystrophy drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Duchenne Muscular Dystrophy Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Corticosteroids
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Prednisolone
      • 6.1.2.2 Prednisone
      • 6.1.2.3 Deflazacort
    • 6.1.3 Market Forecast
  • 6.2 Pain Management Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Therapeutic Approach

  • 7.1 Mutation Suppression
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Exon Skipping
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Steroid Therapy
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Home Care Settings
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 FibroGen Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Italfarmaco S.p.A.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 NS Pharma Inc. (Nippon Shinyaku Co. Ltd.)
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 PTC Therapeutics Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Santhera Pharmaceuticals
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Sarepta Therapeutics Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: Duchenne Muscular Dystrophy Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by Product Type (in %), 2023
  • Figure 5: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by Therapeutic Approach (in %), 2023
  • Figure 6: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Duchenne Muscular Dystrophy Drugs (Corticosteroids) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Duchenne Muscular Dystrophy Drugs (Corticosteroids) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Duchenne Muscular Dystrophy Drugs (Pain Management Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Duchenne Muscular Dystrophy Drugs (Pain Management Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Duchenne Muscular Dystrophy Drugs (Mutation Suppression) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Duchenne Muscular Dystrophy Drugs (Mutation Suppression) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Duchenne Muscular Dystrophy Drugs (Exon Skipping) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Duchenne Muscular Dystrophy Drugs (Exon Skipping) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Duchenne Muscular Dystrophy Drugs (Steroid Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Duchenne Muscular Dystrophy Drugs (Steroid Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Duchenne Muscular Dystrophy Drugs (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Duchenne Muscular Dystrophy Drugs (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Duchenne Muscular Dystrophy Drugs (Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Duchenne Muscular Dystrophy Drugs (Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Duchenne Muscular Dystrophy Drugs (Home Care Settings) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Duchenne Muscular Dystrophy Drugs (Home Care Settings) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: North America: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: North America: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: United States: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: United States: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Canada: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Canada: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Asia-Pacific: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Asia-Pacific: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: China: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: China: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Japan: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Japan: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: India: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: India: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: South Korea: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: South Korea: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Australia: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Australia: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Indonesia: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Indonesia: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Others: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Others: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Europe: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Europe: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Germany: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Germany: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: France: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: France: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: United Kingdom: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: United Kingdom: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Italy: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Italy: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Spain: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Spain: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Russia: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Russia: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Others: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Others: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Latin America: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Latin America: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Brazil: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Brazil: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Mexico: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Mexico: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Others: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Others: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Middle East and Africa: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Middle East and Africa: Duchenne Muscular Dystrophy Drugs Market: Breakup by Country (in %), 2023
  • Figure 72: Middle East and Africa: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Global: Duchenne Muscular Dystrophy Drugs Industry: Drivers, Restraints, and Opportunities
  • Figure 74: Global: Duchenne Muscular Dystrophy Drugs Industry: Value Chain Analysis
  • Figure 75: Global: Duchenne Muscular Dystrophy Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Duchenne Muscular Dystrophy Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Breakup by Product Type (in Million US$), 2024-2032
  • Table 3: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Breakup by Therapeutic Approach (in Million US$), 2024-2032
  • Table 4: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Duchenne Muscular Dystrophy Drugs Market: Competitive Structure
  • Table 7: Global: Duchenne Muscular Dystrophy Drugs Market: Key Players